Host |
Rabbit |
Klon |
ZR340 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
1 ml |
Concentrate |
CE/IVD |
Z2646RL |
-
|
Host |
Rabbit |
Klon |
ZR340 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Astrocytoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
7 ml |
ready-to-use |
CE/IVD |
Z2646RP |
-
|
Host |
Rabbit |
Klon |
ZR340 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
0.5 ml |
Concentrate |
CE/IVD |
Z2646RS |
-
|
Host |
Rabbit |
Klon |
ZR340 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Vorbehandlung |
HIER or PIER |
Positivkontrolle |
Astrocytoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Fragment (around aa 200-300) of human Olig2 protein |
Lokalisation |
Nuclear |
Olig2
|
Zeta Corporation |
ZR340 |
0.1 ml |
Concentrate |
CE/IVD |
Z2646RT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Purified |
Methode |
EL |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the amino acids 37-49 of the native molecule conjugated to KLH |
Osteocalcin (Bone-Gla-Protein, BGP)
|
Zytomed Systems GmbH |
polyclonal |
1 ml |
Purified |
RUO |
615-0033 |
-
|
Host |
Mouse |
Klon |
3G221 |
Format |
Highly Purified |
Methode |
EL, WB, IHC, FL |
Isotyp |
Mouse |
Verdünnung |
Bovine Osteonectin. |
Osteonectin/SPARC
|
Zytomed Systems GmbH |
3G221 |
100 µg |
Highly Purified |
RUO |
216-1000 |
-
|
Host |
Rabbit |
Klon |
EPR23001-88 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Tonsil |
Verdünnung |
- |
Isotyp |
IgG |
Lokalisation |
Cell membrane |
OX / CD134
|
Biocare Medical |
EPR23001-88 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3245G |
-
|
Host |
Rabbit |
Klon |
SP271 |
Format |
Concentrate |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cervical Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human p14ARF protein |
Lokalisation |
Nucleus |
p14ARF
|
Zytomed Systems GmbH |
SP271 |
0.5 ml |
Concentrate |
RUO |
501-5712 |
-
|
Host |
Rabbit |
Klon |
SP271 |
Format |
Concentrate |
Methode |
P, WB, FL |
Vorbehandlung |
EDTA |
Positivkontrolle |
Cervical Carcinoma |
Verdünnung |
1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to the C-terminus of human p14ARF protein |
Lokalisation |
Nucleus |
p14ARF
|
Zytomed Systems GmbH |
SP271 |
1 ml |
Concentrate |
RUO |
501-5714 |
-
|
Host |
Mouse+Rabbit |
Klon |
BC42+EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa + Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic (Brown) + Nucleus and cell membrane (Red) |
p16 + PRAME
|
Biocare Medical |
BC42+EPR20330 |
7 ml |
Ready-to-use |
CE/IVD |
ALI3256DSG7 |
-
|
Host |
Mouse+Rabbit |
Klon |
BC42+EPR20330 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Melanoma |
Verdünnung |
- |
Isotyp |
Mouse IgG1 kappa + Rabbit IgG |
Lokalisation |
Nuclear and cytoplasmic (Brown) + Nucleus and cell membrane (Red) |
p16 + PRAME
|
Biocare Medical |
BC42+EPR20330 |
6 ml |
Ready-to-use |
CE/IVD |
API3256DSAA |
-
|
Host |
Mouse |
Klon |
BC42 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Cervical Cancer |
Verdünnung |
1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Nuclear and cytoplasmic |
p16 INK4a
|
Biocare Medical |
BC42 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3231A |
-
|
Host |
Mouse |
Klon |
BC42 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Cervical Cancer |
Verdünnung |
1:100 |
Isotyp |
IgG1 kappa |
Lokalisation |
Nuclear and cytoplasmic |
p16 INK4a
|
Biocare Medical |
BC42 |
1 ml |
Concentrate |
CE/IVD |
ACI3231C |
-
|
Host |
Mouse |
Klon |
BC42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Tonsil, Cervical Cancer |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Nuclear and cytoplasmic |
p16 INK4a
|
Biocare Medical |
BC42 |
6 ml |
Ready-to-use |
CE/IVD |
API3231AA |
-
|
Host |
Mouse |
Klon |
BC42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Tonsil, Cervical Cancer |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus and cytoplasmic |
p16 INK4a
|
Biocare Medical |
BC42 |
6 ml |
Ready-to-use |
CE/IVD |
AVI3231G |
-
|
Host |
Mouse |
Klon |
BC42 |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
CC1 |
Positivkontrolle |
Tonsil, Cervical Cancer |
Verdünnung |
- |
Isotyp |
IgG1 kappa |
Lokalisation |
Nucleus and cytoplasmic |
p16 INK4a
|
Biocare Medical |
BC42 |
25 ml |
Ready-to-use |
CE/IVD |
AVI3231G25 |
-
|
Host |
Mouse and Rabbit |
Klon |
JC2 + SP6 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
optional |
Positivkontrolle |
Cervical CA |
Isotyp |
IgG2a / Rabbit IgG |
Verdünnung |
Synthetic peptide from 62 base pair region of the human Ki-67 antigen. And purified recombinant prokaryotic full length human P16 INK4 protein |
Lokalisation |
Cytoplasmic and Nuclear |
p16/Ki-67 Cocktail
|
Diagnostic Biosystems |
JC2 + SP6 |
0.5 ml |
Concentrate |
RUO |
RMM001R-05 |
-
|
Host |
Mouse |
Klon |
MX007 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human p16INK4a protein (aa1-156) |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
MX007 |
1.0 ml |
Concentrate |
CE/IVD |
Z2016ML |
-
|
Host |
Mouse |
Klon |
MX007 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human p16INK4a protein (aa1-156) |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
MX007 |
7 ml |
Ready-to-use |
CE/IVD |
Z2016MP |
-
|
Host |
Mouse |
Klon |
MX007 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human p16INK4a protein (aa1-156) |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
MX007 |
0.5 ml |
Concentrate |
CE/IVD |
Z2016MS |
-
|
Host |
Mouse |
Klon |
MX007 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG1 /κ |
Verdünnung |
Recombinant human p16INK4a protein (aa1-156) |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
MX007 |
0.1 ml |
Concentrate |
CE/IVD |
Z2016MT |
-
|
Host |
Mouse |
Klon |
G175-405 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human p16INK4a |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
G175-405 |
1.0 ml |
Concentrate |
CE/IVD |
Z2117ML |
-
|
Host |
Mouse |
Klon |
G175-405 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG2 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human p16INK4a |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
G175-405 |
7 ml |
Ready-to-use |
CE/IVD |
Z2117MP |
-
|
Host |
Mouse |
Klon |
G175-405 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human p16INK4a |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
G175-405 |
0.5 ml |
Concentrate |
CE/IVD |
Z2117MS |
-
|
Host |
Mouse |
Klon |
G175-405 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 |
Isotyp |
IgG2 /κ |
Verdünnung |
A synthetic peptide from the C-terminus of human p16INK4a |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
G175-405 |
0.1 ml |
Concentrate |
CE/IVD |
Z2117MT |
-
|
Host |
Mouse |
Klon |
JC2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified recombinant prokaryotic full length human p16INK4a protein |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
JC2 |
1.0 ml |
Concentrate |
CE/IVD |
Z2567ML |
-
|
Host |
Mouse |
Klon |
JC2 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma |
Verdünnung |
- |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified recombinant prokaryotic full length human p16INK4a protein |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
JC2 |
7 ml |
Ready-to-use |
CE/IVD |
Z2567MP |
-
|
Host |
Mouse |
Klon |
JC2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified recombinant prokaryotic full length human p16INK4a protein |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
JC2 |
0.5 ml |
Concentrate |
CE/IVD |
Z2567MS |
-
|
Host |
Mouse |
Klon |
JC2 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Cervical squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG2a /κ |
Verdünnung |
Purified recombinant prokaryotic full length human p16INK4a protein |
Lokalisation |
Cytoplasm and Nucleus |
p16INK4a
|
Zeta Corporation |
JC2 |
0.1 ml |
Concentrate |
CE/IVD |
Z2567MT |
-
|
Host |
Rabbit |
Klon |
ZR288 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Purified human recombinant fusion p21 protein |
Lokalisation |
Nuclear |
p21
|
Zeta Corporation |
ZR288 |
1 ml |
Concentrate |
CE/IVD |
Z2602RL |
-
|
Host |
Rabbit |
Klon |
ZR288 |
Format |
ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
--- |
Isotyp |
IgG |
Verdünnung |
Purified human recombinant fusion p21 protein |
Lokalisation |
Nuclear |
p21
|
Zeta Corporation |
ZR288 |
7 ml |
ready-to-use |
CE/IVD |
Z2602RP |
-
|
Host |
Rabbit |
Klon |
ZR288 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Purified human recombinant fusion p21 protein |
Lokalisation |
Nuclear |
p21
|
Zeta Corporation |
ZR288 |
0.5 ml |
Concentrate |
CE/IVD |
Z2602RS |
-
|
Host |
Rabbit |
Klon |
ZR288 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Purified human recombinant fusion p21 protein |
Lokalisation |
Nuclear |
p21
|
Zeta Corporation |
ZR288 |
0.1 ml |
Concentrate |
CE/IVD |
Z2602RT |
-
|
Host |
Mouse |
Klon |
DCS-72.F6 |
Format |
Concentrate |
Methode |
F, P, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
p27 (KIP1)
|
Diagnostic Biosystems |
DCS-72.F6 |
1 ml |
Concentrate |
CE/IVD |
MOB281 |
-
|
Host |
Mouse |
Klon |
DCS-72.F6 |
Format |
Concentrate |
Methode |
F, P, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
p27 (KIP1)
|
Diagnostic Biosystems |
DCS-72.F6 |
0.1 ml |
Concentrate |
CE/IVD |
MOB281-01 |
-
|
Host |
Mouse |
Klon |
DCS-72.F6 |
Format |
Concentrate |
Methode |
F, P, IP |
Vorbehandlung |
Citrate |
Positivkontrolle |
Colon Carcinoma |
Verdünnung |
1:25 - 1:50 |
Isotyp |
Mouse IgG1 |
Lokalisation |
Nucleus |
p27 (KIP1)
|
Diagnostic Biosystems |
DCS-72.F6 |
0.5 ml |
Concentrate |
CE/IVD |
MOB281-05 |
-
|
Host |
Mouse |
Klon |
SX53G8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified glutathione S-transferase (GST)-p27Kip1 fusion protein |
Lokalisation |
Nucleus |
p27Kip1
|
Zeta Corporation |
SX53G8 |
1.0 ml |
Concentrate |
CE/IVD |
Z2158ML |
-
|
Host |
Mouse |
Klon |
SX53G8 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
- |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified glutathione S-transferase (GST)-p27Kip1 fusion protein |
Lokalisation |
Nucleus |
p27Kip1
|
Zeta Corporation |
SX53G8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2158MP |
-
|
Host |
Mouse |
Klon |
SX53G8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified glutathione S-transferase (GST)-p27Kip1 fusion protein |
Lokalisation |
Nucleus |
p27Kip1
|
Zeta Corporation |
SX53G8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2158MS |
-
|
Host |
Mouse |
Klon |
SX53G8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Colon carcinoma. |
Verdünnung |
1:50 - 1:200 |
Isotyp |
IgG1 /κ |
Verdünnung |
Purified glutathione S-transferase (GST)-p27Kip1 fusion protein |
Lokalisation |
Nucleus |
p27Kip1
|
Zeta Corporation |
SX53G8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2158MT |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Ready-to-use |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate |
Isotyp |
Ig |
Verdünnung |
A synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40
|
Diagnostic Biosystems |
polyclonal |
6 ml |
Ready-to-use |
CE/IVD |
PDR055 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Ig |
Verdünnung |
A synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40
|
Diagnostic Biosystems |
polyclonal |
1 ml |
Concentrate |
CE/IVD |
RP163 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Ig |
Verdünnung |
A synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40
|
Diagnostic Biosystems |
polyclonal |
0.1 ml |
Concentrate |
CE/IVD |
RP163-01 |
-
|
Host |
Rabbit |
Klon |
polyclonal |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
EDTA |
Positivkontrolle |
Prostate |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Ig |
Verdünnung |
A synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40
|
Diagnostic Biosystems |
polyclonal |
0.5 ml |
Concentrate |
CE/IVD |
RP163-05 |
-
|
Host |
Rabbit |
Klon |
ZR8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized polypeptides from N-terminal domain of p63 |
Lokalisation |
Nucleus |
p40
|
Zeta Corporation |
ZR8 |
1.0 ml |
Concentrate |
CE/IVD |
Z2004RL |
-
|
Host |
Rabbit |
Klon |
ZR8 |
Format |
Ready-to-use |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung squamous cell carcinoma. |
Verdünnung |
- |
Isotyp |
IgG |
Verdünnung |
Synthesized polypeptides from N-terminal domain of p63 |
Lokalisation |
Nucleus |
p40
|
Zeta Corporation |
ZR8 |
7 ml |
Ready-to-use |
CE/IVD |
Z2004RP |
-
|
Host |
Rabbit |
Klon |
ZR8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized polypeptides from N-terminal domain of p63 |
Lokalisation |
Nucleus |
p40
|
Zeta Corporation |
ZR8 |
0.5 ml |
Concentrate |
CE/IVD |
Z2004RS |
-
|
Host |
Rabbit |
Klon |
ZR8 |
Format |
Concentrate |
Reaktivität |
- |
Methode |
P |
Positivkontrolle |
Lung squamous cell carcinoma. |
Verdünnung |
1:100 - 1:200 |
Isotyp |
IgG |
Verdünnung |
Synthesized polypeptides from N-terminal domain of p63 |
Lokalisation |
Nucleus |
p40
|
Zeta Corporation |
ZR8 |
0.1 ml |
Concentrate |
CE/IVD |
Z2004RT |
-
|
Host |
Mouse |
Klon |
BC28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40 (M)
|
Biocare Medical |
BC28 |
0.1 ml |
Concentrate |
CE/IVD |
ACI3066A |
-
|
Host |
Mouse |
Klon |
BC28 |
Format |
Concentrate |
Methode |
P |
Vorbehandlung |
Citrate |
Positivkontrolle |
Lung squamous cell carcinoma |
Verdünnung |
1:50 - 1:100 |
Isotyp |
Rabbit IgG |
Verdünnung |
Synthetic peptide corresponding to amino acids 5-17 of human p40 |
Lokalisation |
Nucleus |
p40 (M)
|
Biocare Medical |
BC28 |
1 ml |
Concentrate |
CE/IVD |
ACI3066C |
-
|